Reasons to Buy �
Understand the current clinical landscape by considering the treatment options available for each patient segment.
� Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
�
�
�
�
Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
Understand the relative strengths and weaknesses of the studies used to gather these data.
Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.
Table of Contents:
1. Report Guidance 5 2. Adjuvant Immunotherapy 6 3. Chemotherapy 7 4. Targeted Therapies 9 5. Pipeline Products 10 6. Changes to Adjuvant Immunotherapy 2016-2022 10 7. Changes to Advanced( Unresectable or Metastatic) Therapies 2016-2022 11 8. Changes to Chemotherapy 2016-2022 11 9. Changes to Immunotherapy 2016-2022 11 10. Changes to Targeted Therapies 2016-2022 12
See More Reports of This Category by Radiant Insights: http:// www. radiantinsights. com / catalog / pharmaceuticals-and-healthcare
Follow Us: